Circulating 20S proteasome in patients with non-metastasized breast cancer

Anticancer Research

Volumn 31, Issue 6, 2011, Pages 2197-2201

  Hoffmann, Oliver ^a   Heubner, Martin ^a   Anlasik, Timur ^b   Winterhalter, Michael ^b   Dahlmann, Burkhardt ^c   Kasimir Bauer, Sabine ^a   Kimmig, Rainer ^a   Wohlschlaeger, Jeremias ^a   Sixt, Stephan Urs ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b Department of Orthopedic Surgery   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Breast cancer; Extracellular proteasome; Ubiquitin proteasome system

Indexed keywords

BIOLOGICAL MARKER; C PROTEASOME; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEASOME; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW; BREAST CANCER; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; METASTASIS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 79960445377     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Harbeck N, Salem M, Nitz U, Gluz O and Liedtke C: Personalized treatment of early-stage breast cancer: present concepts and future directions. Cancer Treat Rev 36(8): 584-594, 2010.
2. Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, Kaul S and Basiert G: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 88: 1652-1658, 1996.
3. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmüller G and Schlimok G: Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342: 525-533, 2000. (Pubitemid 30117892)
4. Solomayer EF, Diel IJ, Salami G, Hahn M, Gollan C, Schütz F and Baster G: Time independence of the prognostic impact of tumor cell detection in the bone marrow of primary breast cancer patients. Clin Cancer Res 7: 4102-4108, 2001. (Pubitemid 34044634)
5. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber G, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A and Pantel K: A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353: 793-802, 2005. (Pubitemid 41215488)
6. Glickman MH and Ciechanover A: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82(2): 373-428, 2002. (Pubitemid 34654457)
7. Adams J: The proteasome: structure, function, and role in the cell. Cancer Treat Rev 29: 3-9, 2003.
8. Ciechanover A and Schwartz AL: The ubiquitin system: pathogenesis of human diseases and drug targeting. Biochim Biophys Acta 1695(1-3): 3-17, 2004. (Pubitemid 39574964)
9. Kisselev AF and Goldberg AL: Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8(8): 739-758, 2001. (Pubitemid 32752454)
10. Lecker SH, Goldberg AL and Mitch WE: Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 17(7): 1807-1819, 2006.
11. Wong BR, Parlati F, Qu K, Demo S, Pray T, Huang J, Payan DG and Bennett MK: Drug discovery in the ubiquitin regulatory pathway. Drug Discov Today 8(16): 746-754, 2003. (Pubitemid 37011246)
12. Golab J, Bauer TM, Daniel V and Naujokat C: Role of the ubiquitin-proteasome pathway in the diagnosis of human diseases. Clin Chim Acta 340(1-2): 27-40, 2004. (Pubitemid 38167506)
13. Wada M, Kosaka M, Saito S, Sano T, Tanaka K and Ichihara A: Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance. J Lab Clin Med 121(2): 215-223, 1993. (Pubitemid 23073128)
14. Sixt SU and Dahlmann B: Extracellular, circulating proteasomes and ubiquitin - Incidence and relevance. Biochim Biophys Acta 1782: 817-823, 2008.
15. Egerer K, Kuckelkorn U, Rudolph PE, Rücken JC, Dörner T, Burmester GR, Kloetzel PM and Feist E: Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases. J Rheumatol 29(10): 2045-2052, 2002.
16. Roth GA, Moser B, Krenn C, Roth-Walter F, Hetz H, Richter S, Brunner M, Jensen-Jarolim E, Wolner E, Hoetzenecker K, Boltz-Nitulescu G and Ankersmit HJ: Heightened levels of circulating 20S proteasome in critically ill patients. Eur J Clin Invest 35(6): 399-403, 2005. (Pubitemid 40826839)
17. Sixt SU, Adamzik M, Spyrka D, Saul B, Hakenbeck J, Wohlschlaeger J, Costabel U, Kloss A, Giesebrecht J, Dahlmann B and Peters J: Alveolar extracellular 20S proteasome in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 179: 1098-1106, 2009.
18. Stoebner PE, Lavabre-Bertrand T, Henry L, Guiraud I, Carillo S, Dandurand M, Joujoux JM, Bureau JP and Meunier L: High plasma proteasome levels are detected in patients with metastatic malignant melanoma. Br J Dermatol 152(5): 948-953, 2005. (Pubitemid 40704935)
19. Lavabre-Bertrand T, Henry L, Carillo S, Guiraud I, Ouali A, Dutaud D, Aubry L, Rossi JF and Bureau JP: Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies. Cancer 92(10): 2493-2500, 2001. (Pubitemid 33049430)
20. Dutaud D, Aubry L, Henry L, Levieux D, Hendil KB, Kuehn L, Bureau JP and Ouali A: Development and evaluation of a sandwich ELISA for quantification of the 20S proteasome in human plasma. J Immunol Methods 260(1-2): 183-193, 2002. (Pubitemid 34132884)
21. Heubner M, Wimberger P, Dahlmann B, Kasimir-Bauer S, Kimmig R, Peters J, Wohlschlaeger J and Sixt SU: The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer. Gynecol Oncol 120(2): 233-238, 2011.
22. + cells: a new link between proteasome activity and estrogen signaling in breast cancer. Oncogene 29(10): 1509-1518, 2010.
23. Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C, Schindlbeck C, Wallwiener D, Borgen E, Naume B, Pantel K and Solomayer E: A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 107: 885-892, 2006. (Pubitemid 44291136)
24. Borgen E, Naume B, Nesland JM, Kvalheim G, Beiske K, Fodstad O, Diel I, Solomayer EF, Theocharous P, Coombes RC, Smith BM, Wunder E, Marolleau JP, Garcia J and Pantel K: Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1: 377-388, 1999.
25. Zoeger A, Blau M, Egerer K, Feist E and Dahlmann B: Circulating proteasomes are functional and have a subtype pattern distinct from 20S proteasomes in major blood cells. Clin Chem 52: 2079-2086, 2006. (Pubitemid 44658211)
26. Attaix D, Combaret L, Tilignac T and Taillandier D: Adaptation of the ubiquitin-proteasome proteolytic pathway in cancer cachexia. Mol Biol Rep 26(1-2): 77-82, 1999. (Pubitemid 29223255)
27. Shah JJ and Orlowski RZ: Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 25(11): 1964-1979, 2009.
28. Iijima M, Momose I and Ikeda D: TP-110, a new proteasome inhibitor, down-regulates IAPs in human multiple myeloma cells. Anticancer Res 29(4): 977-985, 2009.
29. Rajkumar SV, Richardson PG, Hideshima T and Anderson KC: Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23(3): 630-639, 2005. (Pubitemid 46224241)
30. Awada A, Albaneil J, Canney PA, Dirix LY, Gil T, Cardoso F, Gascon P, Piccart MJ and Baselga J: Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. Br J Cancer 98(9): 1500-1507, 2008. (Pubitemid 351652337)
31. Dees EC, O'Neil BH, Lindley CM, Collichio F, Carey LA, Collins J, Riordan WJ, Ivanova A, Esseltine D and Orlowski RZ: A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. Cancer Chemother Pharmacol 65(1): 99-107, 2008.
32. Engel RH, Brown JA, Von Roenn JH, O'Regan RM, Bergan R, Badve S, Rademaker A and Gradishar WJ: A phase II study of single-agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Invest 25(8): 733-737, 2007. (Pubitemid 350223168)
33. Park YM, Cho JY, Koo YD and Lee YJ: Effects of inhibiting the proteasomal degradation of estrogen receptor alpha on estrogen receptor alpha activation under hypoxic conditions. Biol Pharm Bull 32(12): 2057-2060, 2009.